Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature.Neurofibromatosis type 2 (NF-2) is an autosomal dominant inherited disease caused by heterozygous mutations in the NF-2 tumor suppressor gene.  The use of bevacizumab has made many progresses in recent years in NF-2 patients.  We report a case of a young patient treated with more than 100 administration of bevacizumab, with clinical and instrumental benefits.
bevacizumab
Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature.Neurofibromatosis type 2 (NF-2) is an autosomal dominant inherited disease caused by heterozygous mutations in the NF-2 tumor suppressor gene.  The use of bevacizumab has made many progresses in recent years in NF-2 patients.  We report a case of a young patient treated with more than 100 administration of bevacizumab, with clinical and instrumental benefits.
bevacizumab
Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature.Neurofibromatosis type 2 (NF-2) is an autosomal dominant inherited disease caused by heterozygous mutations in the NF-2 tumor suppressor gene.  The use of bevacizumab has made many progresses in recent years in NF-2 patients.  We report a case of a young patient treated with more than 100 administration of bevacizumab, with clinical and instrumental benefits.
bevacizumab
Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature.Neurofibromatosis type 2 (NF-2) is an autosomal dominant inherited disease caused by heterozygous mutations in the NF-2 tumor suppressor gene.  The use of bevacizumab has made many progresses in recent years in NF-2 patients.  We report a case of a young patient treated with more than 100 administration of bevacizumab, with clinical and instrumental benefits.
bevacizumab
Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature.Neurofibromatosis type 2 (NF-2) is an autosomal dominant inherited disease caused by heterozygous mutations in the NF-2 tumor suppressor gene.  The use of bevacizumab has made many progresses in recent years in NF-2 patients.  We report a case of a young patient treated with more than 100 administration of bevacizumab, with clinical and instrumental benefits.
bevacizumab